Massachusetts Melanoma Foundation – Trademark Portfolio
Entity Type: 03
Massachusetts Melanoma Foundation holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 16 (Paper Goods) — 2 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 7 Nice Classification classes. The owner is based in Concord, MA.
66 Commonwealth Aveniue
Concord, MA 01742
Showing of trademarks Trademarks
Trademark Classifications
Massachusetts Melanoma Foundation's trademark portfolio spans 7 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Education; providing of training; entertainment; sporting and cultural activities
Advertising; business management; business administration; office functions
Legal services; security services for the protection of property and individuals
Insurance; financial affairs; monetary affairs; real estate affairs
Frequently Asked Questions
How many trademarks does Massachusetts Melanoma Foundation have?
Massachusetts Melanoma Foundation has 3 U.S. trademarks filed with the USPTO.
What trademark classes does Massachusetts Melanoma Foundation file in?
Massachusetts Melanoma Foundation files trademarks across 7 Nice Classification classes. The most active classes are Class 16 (Paper Goods), Class 9 (Computers & Electronics), Class 41 (Education & Entertainment), Class 35 (Advertising & Business), Class 45 (Legal & Security Services). Class 16 covers paper and cardboard; printed matter; bookbinding material; photographs; stationery.
What is Massachusetts Melanoma Foundation's trademark registration success rate?
Massachusetts Melanoma Foundation has a 0% trademark registration rate, with 0 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.